Evidence map›Paper›PMID 42108418›Full record

ArticleDiabetes, obesity & metabolism2026

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability.

Gian Paolo Fadini, Mario Luca Morieri, Carlotta Boscaro, Benedetta Maria Bonora, Andrea Cignarella

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gian Paolo FadiniDepartment of Medicine, University of Padova, Padua, Italy.ORCID 0000-0002-6510-2097
Mario Luca MorieriDepartment of Medicine, University of Padova, Padua, Italy.
Carlotta BoscaroDepartment of Medicine, University of Padova, Padua, Italy.
Benedetta Maria BonoraDepartment of Medicine, University of Padova, Padua, Italy.
Andrea CignarellaDepartment of Medicine, University of Padova, Padua, Italy.

Funding

Università degli Studi di Padova
6 · The paper itself

Abstract

aimsOral semaglutide absorption is subject to inter-individual variability. We investigated whether estimated individual exposure (eC MATERIALS AND

methodsWe retrospectively included patients initiating oral semaglutide to calculate eC

resultsWe analysed 256 participants (31.6% women, mean age 65.6 years). During a median follow-up of 19 months, HbA1c declined by 0.7% and body weight by 7.5%; 41.8% of patients reported GI side effects. Both dose and eC

conclusionsAlthough estimated and not measured, the exposure to oral semaglutide may provide outcome-dependent information. While the prescribed dose seems sufficient to predict glycaemic response, estimated exposure provides additional value for weight loss and GI tolerability.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutideWeight LossAdministration, OralAgedBlood GlucoseDose-Response Relationship, DrugFemaleGastrointestinal DiseasesGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutidepharmacokineticsreal‐world evidencesemaglutidetype 2 diabetes

Identifiers

PMID42108418
PMCPMC13243947

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.